$ALKS

snyderman nancy lynn MD sold $2.2M of ALKS

snyderman nancy lynn MD sold 44,472 shares of Alkermes plc. (ALKS) at $50.35 ($2.24M total) on 2026-08-03.

Original reporting
SEC EDGAR · snyderman nancy lynn MD
Published Aug 3, 2026, 11:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

A director open-market sale of $2.24M is disclosed, including trade date, share count, price, and remaining holdings; there is no accompanying operational or financial update.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a durable repricing without corroborating fundamental news.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still lacks context on taxes, personal liquidity needs, or whether other insiders made offsetting purchases.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-03 (same day as transaction)

Background

The article is an SEC Form 4 insider transaction disclosure for Alkermes plc.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Alkermes director Nancy Lynn Snyderman sold 44,472 shares in an open-market transaction worth about $2.24M, filed on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction size, price, and post-sale holdings, but no accompanying company news or guidance change.

Market effects

No clear sector read-through from a single director sale without additional company or industry disclosures.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity or diversification and does not necessarily signal reduced confidence, especially without any other negative company-specific news.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider sale disclosure.

  • Nancy Lynn Snyderman, MD

    Director who sold 44,472 shares at $50.3480 per share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.